Firefly inks latest commercial agreement for use of its fda-cleared bna™ platform in groundbreaking precision neuroscience research

– institute of human genetics at heidelberg university hospital ongoing eeg biomarker study on 15q13.3 cnvs – – collaboration aims to uncover novel insights into the brain's functional architecture in rare genetic conditions – – building and growing a license business is an increasingly important pillar of firefly's commercial strategy – kenmore, n.y., july 14, 2025 (globe newswire) -- firefly neuroscience, inc. (“firefly” or the “company”) (nasdaq: aiff), an artificial intelligence (“ai”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to highlight its ongoing collaboration with prof.
AIFF Ratings Summary
AIFF Quant Ranking